|
15 Jul 2025 |
Divi's Laboratories
|
Consensus Share Price Target
|
6778.50 |
6439.76 |
- |
-5.00 |
hold
|
|
|
|
|
15 Aug 2023
|
Divi's Laboratories
|
Prabhudas Lilladhar
|
6778.50
|
3000.00
|
3730.55
(81.70%)
|
|
Sell
|
|
|
|
|
15 Aug 2023
|
Divi's Laboratories
|
Motilal Oswal
|
6778.50
|
3430.00
|
3730.55
(81.70%)
|
Target met |
Neutral
|
|
|
|
|
24 May 2023
|
Divi's Laboratories
|
Geojit BNP Paribas
|
6778.50
|
3783.00
|
3383.15
(100.36%)
|
Target met |
Buy
|
|
|
|
|
23 May 2023
|
Divi's Laboratories
|
SMC online
|
6778.50
|
|
3385.80
(100.20%)
|
|
Results Update
|
|
|
|
|
22 May 2023
|
Divi's Laboratories
|
ICICI Securities Limited
|
6778.50
|
3560.00
|
3265.00
(107.61%)
|
Target met |
Accumulate
|
|
|
Divi’s Laboratories’ (Divi’s) has posted its highest ever quarterly sales in generics segment of Rs10bn, up 42% YoY in Q4FY23, though a surge in raw material price and overhead cost has impacted margins (down 1,670bps YoY). Management has indicated a gradual improvement in margins Q1FY24 onwards as it has exhausted high-priced inventory and raw material prices are also declining.
|
|
22 May 2023
|
Divi's Laboratories
|
Motilal Oswal
|
6778.50
|
2900.00
|
3265.00
(107.61%)
|
|
Neutral
|
|
|
|
|
21 May 2023
|
Divi's Laboratories
|
Prabhudas Lilladhar
|
6778.50
|
2700.00
|
3098.30
(118.78%)
|
|
Hold
|
|
|
|
|
21 May 2023
|
Divi's Laboratories
|
ICICI Direct
|
6778.50
|
3575.00
|
3098.30
(118.78%)
|
Target met |
Buy
|
|
|
|
|
19 Mar 2023
|
Divi's Laboratories
|
Motilal Oswal
|
6778.50
|
2620.00
|
2791.50
(142.83%)
|
|
Neutral
|
|
|
|
|
06 Feb 2023
|
Divi's Laboratories
|
ICICI Securities Limited
|
6778.50
|
3024.00
|
2884.35
(135.01%)
|
Target met |
Hold
|
|
|
Divi’s Laboratories’ (Divi’s) Q3FY23 performance was well below our estimates. Consolidated revenues fell 7.9% QoQ to Rs17.1bn (I-Sec: Rs20.5bn), EBITDA margin slipped to its lowest-ever at 23.9% (-2,010bps YoY, -960bpsQoQ)
|